These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30694825)

  • 1. Dyslipidemia in nonalcoholic fatty liver disease.
    Amor AJ; Perea V
    Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):103-108. PubMed ID: 30694825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
    Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
    J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease.
    Garcia AE; Kasim N; Tamboli RA; Gonzalez RS; Antoun J; Eckert EA; Marks-Shulman PA; Dunn J; Wattacheril J; Wallen T; Abumrad NN; Flynn CR
    PLoS One; 2015; 10(11):e0142676. PubMed ID: 26599819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting lipoproteins in nonalcoholic fatty liver disease.
    Nemes K; Åberg F
    Curr Opin Lipidol; 2017 Aug; 28(4):355-360. PubMed ID: 28441156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.
    Patel S; Siddiqui MB; Roman JH; Zhang E; Lee E; Shen S; Faridnia M; Mintini RJ; Boyett S; Idowu MO; Sanyal AJ; Luketic VA; Siddiqui MS
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2202-2204. PubMed ID: 33007508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.
    Chait A; Goldberg I
    Curr Diab Rep; 2017 Sep; 17(11):112. PubMed ID: 28956258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
    Taskinen MR; Borén J
    Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males.
    Peng K; Mo Z; Tian G
    Am J Med Sci; 2017 Mar; 353(3):236-241. PubMed ID: 28262209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
    Farnier M; Zeller M; Masson D; Cottin Y
    Arch Cardiovasc Dis; 2021 Feb; 114(2):132-139. PubMed ID: 33546998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study.
    Ren XY; Shi D; Ding J; Cheng ZY; Li HY; Li JS; Pu HQ; Yang AM; He CL; Zhang JP; Ma YB; Zhang YW; Zheng TZ; Bai YN; Cheng N
    Lipids Health Dis; 2019 Feb; 18(1):47. PubMed ID: 30744645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A; Chew GT; Watts GF
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.
    Corey KE; Chalasani N
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1077-84; quiz e59-60. PubMed ID: 23962548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
    Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
    Musunuru K; Kathiresan S
    Circ Res; 2016 Feb; 118(4):579-85. PubMed ID: 26892959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.